Teva R&D Day - Press Kit and Media Assets

Access materials about Teva's R&D Day, including press releases, reports and media resources.   
 
Discover what’s next in Teva R&D

 

Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030

Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease

The Future of R&D Is Powered by Partnerships
Two men smiling outdoors

Tourette Syndrome: Causes, Symptoms and Long-Term Effects

Understanding Schizophrenia: The Human Impact, the Clinical Challenges and the Importance of Stability in Care

Watch Shira tell her story about navigating childhood with Tourette Syndrome.

Transcript video

I know I'm gonna be at a point where my face will start to depigment as well. I just have to keep on accepting myself for how I look, how I'm changing. As I'm changing and I'm changing every day. It feels like the medical establishment feels like this is just cosmetic, but people don't think about how the cosmetic part can affect you. People don't think about how it could mess with your head in some ways with your self-esteem.

Watch Sally and Michael share their challenges and triumphs.

Contacts for Media Inquiries

United States

 

tel: +1-973-2653670

Israel & Corporate

Email
 

tel: +972-3-9062645

Europe

Email